Mechanisms that can be postulated are a direct influence of obesity on drug pharmacokinetics and an inflammatory and therapy-resistant state induced by AT by the release of specific adipocytokines that are increased in RA patients and are able to increase the expression of inflammatory cytokines, such as TNF and IL-6. The gene discussed is IL6; the disease is Obesity.